In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab (Q57374767)
Jump to navigation
Jump to search
scientific article published on 01 November 2007
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab |
scientific article published on 01 November 2007 |
Statements
In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab (English)
Sonia Zorzet
Fleur Bossi
Roberto Marzari
Alberto Amadori
Francesco Tedesco
1 November 2007